TheStreet upgraded shares of BioLife Solutions (NASDAQ:BLFS) from a c rating to a b- rating in a report released on Friday, TheStreetRatingsTable reports.
Other analysts also recently issued research reports about the stock. ValuEngine raised shares of BioLife Solutions from a sell rating to a hold rating in a report on Saturday, November 23rd. BidaskClub upgraded shares of BioLife Solutions from a hold rating to a buy rating in a research report on Monday, November 25th. Northland Securities lifted their price objective on shares of BioLife Solutions from $18.00 to $22.00 and gave the company an outperform rating in a research note on Wednesday, September 4th. Maxim Group set a $26.00 price objective on shares of BioLife Solutions and gave the company a buy rating in a research report on Tuesday, September 17th. Finally, Oppenheimer began coverage on BioLife Solutions in a research note on Wednesday, November 20th. They set an outperform rating and a $22.00 target price for the company. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $19.00.
Shares of BioLife Solutions stock opened at $15.77 on Friday. The company has a quick ratio of 5.33, a current ratio of 6.49 and a debt-to-equity ratio of 0.01. BioLife Solutions has a 12-month low of $9.15 and a 12-month high of $22.44. The company has a market capitalization of $342.57 million, a price-to-earnings ratio of 112.64, a PEG ratio of 20.94 and a beta of 1.33. The firm’s 50-day moving average price is $16.54 and its two-hundred day moving average price is $17.66.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC bought a new position in shares of BioLife Solutions during the first quarter valued at $2,684,000. Roubaix Capital LLC grew its stake in shares of BioLife Solutions by 165.9% in the second quarter. Roubaix Capital LLC now owns 120,313 shares of the medical equipment provider’s stock worth $2,039,000 after purchasing an additional 75,068 shares during the last quarter. Alpine Woods Capital Investors LLC bought a new stake in shares of BioLife Solutions in the second quarter worth $170,000. JPMorgan Chase & Co. bought a new stake in shares of BioLife Solutions in the second quarter worth $30,000. Finally, Menta Capital LLC acquired a new stake in BioLife Solutions in the second quarter valued at $202,000. 50.22% of the stock is currently owned by hedge funds and other institutional investors.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
Read More: What is a Candlestick Chart?
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.